Disclosure Of Interests In Other Entities [Text Block]

Innate Pharma - Filing #882171

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31
Disclosure of interests in other entities [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	138 256 EUR	—	—	—	—	173 451 EUR	—	—	—	—
Non-current assets	129 241 EUR	—	—	—	—	133 972 EUR	—	—	—	—
Current liabilities	79 886 EUR	—	—	—	—	45 488 EUR	—	—	—	—
Non-current liabilities	80 169 EUR	—	—	—	—	105 959 EUR	—	—	—	—
Revenue	—	—	—	24 703 EUR	—	—	69 773 EUR	—	—	—
Profit (loss)	—	52 809 EUR	—	52 809 EUR	—	—	63 984 EUR	63 984 EUR	—	—
Comprehensive income	—	52 809 EUR	101,000 EUR	52 708 EUR	805,000 EUR	—	63 962 EUR	63 984 EUR	827,000 EUR	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Profit (loss) from continuing operations	—	—	—	45 478 EUR	—	—	829,000 EUR	—	—	—
Profit (loss) from discontinued operations	—	—	—	7 331 EUR	—	—	63 155 EUR	—	—	—
Other comprehensive income	—	—	—	101,000 EUR	—	—	22,000 EUR	—	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	103 756 EUR	—	—	—	—	136 792 EUR	—	—	—	202 887 EUR
Tax expense (income)	—	—	—	— EUR	—	—	— EUR	—	—	—